SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Quantech (QQQQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bill Schrader who wrote (262)4/23/1998 4:31:00 PM
From: gaddis  Read Replies (1) of 338
 
My two cents : I think a number of factors could influence a price rise in the stock. First is obviously FDA approval. Second is the establishment of a marketing agreement with a corporate partner (possibly Perkin-Elmer) and last, but not least, is a substantial equity investment in QQQQ by a third party (again Perkin-Elmer). These developments could take Quantech to an entirely different level. One thing to remember is that SPR technology has the potential to be used in a number of different indications in a near-patient setting, so Quantech need not be labeled a one-trick pony if they receive FDA approval for the AMI diagnostic. I think the market has underplayed or ignored the significance of a possible growing alliance between PKN and Quantech. In any event, the markets are very large, and the company has achieved a number of significant milestones. Worth watching.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News